Accordingly, the NCCN guidelines recommend trastuzumab in combination with a fluoropyrimidine and a platinum-containing drug as first-line treatment for HER2-positive (IHC-confirmed or FISH-confirmed) advanced gastric cancer. Here, ERBB2 is linked to gastric cancer.